• Clinical Insights

Frequently asked questions: buprenorphine-containing products

Mar 6th, 2023

Have questions on buprenorphine-containing products?
You’re not alone.

See below for answers to your common questions surrounding these popular medication-assisted treatment prescriptions.

  • What is buprenorphine and what is it used for?
    • Buprenorphine is a Food and Drug Administration (FDA) approved medication used to treat opioid use disorder (OUD). It is the first medication for treating OUD that can be prescribed and/or dispensed in physician offices, significantly increasing access to treatment for OUD.
  • What is Suboxone® and what is it used for?
    • Suboxone® is a medicine that fuses buprenorphine and naloxone – a medication used to reverse or reduce the effects of opioids – that works to decrease the severity of withdrawal symptoms and reduce a patient’s dependence on opioids.
  • What is Sublocade® and what is it used for?
    • Sublocade® is an extended-release form of buprenorphine that continuously releases and sustains medicine levels throughout the month. It blocks the rewarding effects of opioids, and when paired with a full treatment plan can be an effective tool in combatting opioid use disorder. Prior to starting the injectable Sublocade®, a prescriber must induce and adjust treatment with eight to 24 milligrams of a transmucosal buprenorphine-containing product for a minimum of seven days to ensure tolerability.
  • How is Sublocade® administered?
    • Sublocade® is injected subcutaneously by a treatment provider as a liquid and, once inside the body, turns to a solid gel called a depot. The depot gradually releases buprenorphine at a controlled rate all month. Please note – pharmacists are not currently permitted to administer Sublocade®.
  • Is Sublocade® a part of a Risk Evaluation and Mitigation Strategies (REMS) program?
    • Yes, for safety reasons Sublocade® is included in a REMS program. Only certain pharmacies can dispense Sublocade® and it can only be dispensed to a licensed medical provider, not to individual consumers. Furthermore, Sublocade® can only be delivered to a prescriber’s DEA registered address.
  • Why does the Substance Abuse and Mental Health Services Administration (SAMSHA) recommend a medical exam before prescribing Suboxone®?
    • Patients living with opioid use disorder often have comorbidities or other health concerns that are occurring alongside their opioid use disorder diagnosis. Additionally, anytime you start a patient on a new drug therapy, its best to have a baseline understanding of the patient’s health profile. For these reasons and more, a medical exam is recommended before prescribing Suboxone® for a patient.
  • Are patients billed directly for Sublocade® treatment?
    • Yes, the patient’s insurance plan is billed directly

Want to learn more?

Curious how medication-assisted treatment can help support your patients? Contact us today and we’ll be in touch.

"*" indicates required fields

Does your organization currently partner with Genoa?*
This field is for validation purposes and should be left unchanged.

Recent Posts

  • Blog Post
Genoa Pharmacist faces winter snowstorm to deliver consumers’ medications

When Watertown, New York, Pharmacist Meredith Sullivan made the call to close her pharmacy in preparation for an incoming snowstorm on Friday, Dec. 23, she wondered how the pharmacy’s closure...

  • Pharmacy Openings
Announcing three new pharmacy openings!

We’re excited to announce the opening of three pharmacies last month. We welcome all new pharmacy staff to the team and are excited to partner with these organizations to serve...

  • Clinical Insights
Frequently asked questions: buprenorphine-containing products

Information and sources on buprenorphine-containing products were taken from www.sublocade.com and www.suboxone.com.

  • Clinical Insights
What’s on the horizon: four emerging trends in the medication-assisted treatment space

1X-Waiver no longer need to treat opioid use disorder. (2023, January 13). ACEP. 2. Sublocade. 3.BMC launces app to help providers treat patients with opioid use disorder. (2021, March 22)....